– USA, CA – Cerus Corporation (Nasdaq: CERS) today announced the appointment of Ann Lucena, CEO of San Ramon Regional Medical Center, to its Board of Directors.
“We are delighted to welcome Ann to Cerus’ Board of Directors,” said Board Chair, Daniel Swisher. “Ann is an accomplished healthcare executive who has built an impressive track record managing San Ramon Regional Medical Center over the last several years. Her addition to the Board provides us with the perspective and experiences of the healthcare provider community, which we believe will be invaluable as Cerus continues to grow and expand its product portfolio in blood centers and hospitals around the globe.”
About Ann Lucena
Prior to her role at San Ramon Regional Medical Center, Ms. Lucena served as Chief of Staff for the President of Hospital Operations at Tenet Healthcare. Ms. Lucena also has experience in healthcare consulting serving several health systems across the US.
She also serves as the chairperson of the board overseeing the joint venture between John Muir Health and San Ramon Regional Medical Center.
“It is an exciting time at Cerus as the company is at the forefront of a paradigm shift in transfusion medicine,” said Ms. Lucena. “In my experience working with a variety of medical professionals, I believe that the safety of the blood supply as a top priority resonates with virtually every healthcare specialty, particularly as blood products have the potential to impact patients every day. Through the COVID-19 pandemic, it has become abundantly clear that healthcare systems must prepare for the future, including concerning the blood supply. I am looking forward to working alongside Dan, Obi, and the rest of the Cerus Board and management team.”
A graduate of Stanford University, Ms. Lucena dual-majored in Spanish and human biology before earning her MBA at Harvard Business School.
About Cerus Corporation
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
For more information: https://www.cerus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.